Helixmith Plunges On Warning Of Possible Offering Delay
Investment Losses Also Concern Shareholders
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.
